Hyderabad, India and Princeton, NJ, USA. May 15, 2019— Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today
announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent
generic version of Cubicin®
for Injection, approved by the U.S. Food and Drug Administration (USFDA).
The Cubicin®
for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately
$640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.
Dr. Reddy’s Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major
markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
